These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26634942)

  • 21. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
    Holton M; Thorne C; Goldstein AT
    Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?
    Kearley-Shiers K; Holloway D; Janice Rymer ; Bruce D
    Post Reprod Health; 2022 Dec; 28(4):237-243. PubMed ID: 36300276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.
    Kingsberg SA; Kroll R; Goldstein I; Kushner H; Bernick B; Graham S; Mirkin S; Constantine GD
    Menopause; 2017 Aug; 24(8):894-899. PubMed ID: 28195995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
    Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [No Abstract]   [Full Text] [Related]  

  • 30. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
    Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
    Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
    Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
    Bouchard C; Labrie F; Derogatis L; Girard G; Ayotte N; Gallagher J; Cusan L; Archer DF; Portman D; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
    Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
    Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
    Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
    Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
    Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction.
    Vale F; Rezende C; Raciclan A; Bretas T; Geber S
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():92-95. PubMed ID: 30677618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.